RxDoctor Payments DataLook up a doctor →

John Harris, MD

Internal Medicine · Bellevue, NENPI 1043360043

Payments from drug & device makers

$15,412in general payments, 2019–2025

Across 880 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • GSK$895
  • Pfizer$856
  • plus $7K from 50 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)144$2,054
AstraZeneca48$1,619
Amgen92$1,397
Novo Nordisk92$1,285
GSK55$895
Pfizer55$856
Lilly USA, LLC48$840
Johnson & Johnson40$765
Bayer35$561
Biohaven Pharmaceuticals, Inc.18$499
Sanofi-aventis U.S. LLC16$437
Novartis24$393
Aimmune Therapeutics, Inc.5$383
Astellas Pharma US Inc15$332
Boehringer Ingelheim17$254
Otsuka America Pharmaceutical, Inc.14$245
Amarin Pharma, Inc.14$228
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$201
Takeda Pharmaceuticals U.S.A., Inc.14$168
Kowa Pharmaceuticals America, Inc.11$151
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$143
E.r. Squibb & Sons, L.L.C.9$131
Axsome Therapeutics, Inc.7$116
Antares Pharma, Inc.6$115
Abbott6$110
Esperion Therapeutics, Inc.6$89
Nestle Healthcare Nutrition Inc.5$86
Sumitomo Pharma America, Inc.5$86
Merck6$85
Xeris Pharmaceuticals, Inc.4$82
Scilex Pharmaceuticals Inc.4$74
Lundbeck LLC5$73
Biohaven Pharmaceutical Holding Company Ltd.4$67
Boston Scientific3$64
Mylan Specialty L.p.3$43
Idorsia Pharmaceuticals US Inc3$41
Almatica Pharma LLC2$36
Edwards Lifesciences2$33
Ironwood Pharmaceuticals, Inc2$33
Sunovion Pharmaceuticals Inc.2$31
Biogen2$29
Kerecis Limited1$29
Medicure Pharma Inc.1$28
Arbor Pharmaceuticals, Inc.2$25
Lexicon Pharmaceuticals, Inc.1$22
Vanda Pharmaceuticals Inc.1$22
Phathom Pharmaceuticals, Inc.3$21
Seqirus USA Inc1$17
Genentech USA, Inc.1$16
Circassia Inc.1$16
Daiichi Sankyo Inc.1$16
Ultragenyx Pharmaceutical Inc.1$15
Jazz Pharmaceuticals Inc.1$15
Exact Sciences1$14
Actelion Pharmaceuticals US, Inc.1$13
Acadia Pharmaceuticals Inc1$13

How this compares

$15,412 in reported general payments places this provider in the 95th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$267,639
Medicare patients
804
Services billed
14,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Bellevue

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →